Preliminary data from an ongoing phase IIb study of no carrier added 131I-iobenguane (nca-MIBG) in patients with malignant pheochromocytoma (Pheo).
D. A. Pryma
Research Funding - Molecular Insight Pharmaceuticals
J. A. Barrett
Employment or Leadership Position - Molecular Insight Pharmaceuticals
Stock Ownership - Molecular Insight Pharmaceuticals
R. E. Coleman
Honoraria - Molecular Insight Pharmaceuticals
Research Funding - Molecular Insight Pharmaceuticals
R. Noto
Research Funding - MolecularMD
C. Jimenez
Research Funding - Molecular Insight Pharmaceuticals
M. H. Pampaloni
Research Funding - Molecular Insight Pharmaceuticals
A. N. Serafini
Research Funding - Molecular Insight Pharmaceuticals
R. L. Wahl
Research Funding - Molecular Insight Pharmaceuticals
L. Kostakoglu
Research Funding - Molecular Insight Pharmaceuticals
N. D. LaFrance
Stock Ownership - Molecular Insight Pharmaceuticals
J. W. Babich
Employment or Leadership Position - Molecular Insight Pharmaceuticals